ライフサイエンスコーパス: opioid analgesic

1 d analgesics) and strong to severe pain (for opioid analgesics).

2 the treating surgeon, which consisted of an opioid analgesic.

3 and diversion of pharmaceuticals, primarily opioid analgesics.

4 tor target for both endogenous and exogenous opioid analgesics.

5 ates the hypnotic response to high levels of opioid analgesics.

6 , motivating efforts toward developing novel opioid analgesics.

7 for standard treatments such as radiation or opioid analgesics.

8 s had symptomatic, metastatic HRPC requiring opioid analgesics.

9 ide-effect profiles over currently available opioid analgesics.

10 iation of metastatic bony pain compared with opioid analgesics.

11 phine or other conventional bimodally-acting opioid analgesics.

12 (OIH) is a serious adverse event produced by opioid analgesics.

13 s started opioid analgesics and 6.3% stopped opioid analgesics.

14 T-CP) is a safe and effective alternative to opioid analgesics.

15 pmental consequences of prenatal exposure to opioid analgesics.

16 igh interest target for the discovery of non-opioid analgesics.

17 n thresholds and an increased sensitivity to opioid analgesics.

18 to alleviate OIH, a serious adverse event of opioid analgesics.

19 hat Na(V)1.7 blockers could be effective non-opioid analgesics.

20 ptor (MOR), the target of morphine and other opioid analgesics.

21 tipation (OIC) is a common adverse effect of opioid analgesics.

22 arch for a new generation of lower liability opioid analgesics.

23 ted an extremely unbalanced global access to opioid analgesics.

24 t ligands to serve as potential nonaddictive opioid analgesics.

25 e approach for pain management is the use of opioid analgesics.

26 ioid receptor (muOR) is the major target for opioid analgesics.

27 re dependent on opioids to transition to non-opioid analgesics.

28 named RGSz1 in responses to clinically used opioid analgesics.

29 at would allow for lower-dose utilization of opioid analgesics.

30 e effects of two of the most clinically used opioid analgesics.

31 e effects of two of the most clinically used opioid analgesics.

32 which Mg(2+) leads to increased efficacy of opioid analgesics.

33 nzylisoquinoline alkaloid (BIA) precursor to opioid analgesics.

34 uropathic pain states that are refractive to opioid analgesics.

35 ug Administration (FDA) for new approvals of opioid analgesics.

36 oagulants, antibiotics, diabetes agents, and opioid analgesics.

37 therapies as safe and potentially abuse-free opioid analgesics.

38 nal Cav2.3 channels as potential targets for opioid analgesics.

39 ) have been proposed as an improved class of opioid analgesics.

40 a strong therapeutic advantage over standard opioid analgesics.

41 f a new class of drugs known collectively as opioid analgesics.

42 making progress in controlling the abuse of opioid analgesics.

43 ate to severe pain that needs treatment with opioid analgesics.

44 nt at this receptor and improve upon current opioid analgesics.

45 mitigate the need for standard postoperative opioid analgesics.

46 strategy for the production of longer acting opioid analgesics.

47 r (MOR) is the principle molecular target of opioid analgesics.

48 ain (1.22; 1.20-1.24; p < 0.001), receipt of opioid analgesics (1.86; 1.83-1.90; p < 0.001), and fata

49 ore the crash and 6.0% after the crash), and opioid analgesics (15.4% before the crash and 17.5% afte

50 significantly lower postpartum use of rescue opioid analgesics (19 women [13.3%] vs 37 women [25.5%];

51 The recent and precipitous increase in opioid analgesic abuse and overdose has inspired investi

52 As prescription opioid analgesic abuse rates rise, so does the need to u

53 e to increases in the health consequences of opioid analgesic abuse.

54 brain cytochrome P450 (P450) activity in mu opioid analgesic action, we generated a mutant mouse wit

55 These findings indicate altered endogenous opioid analgesic activity in FM and suggest a possible r

56 ute or chronic pain or to enhance endogenous opioid analgesic activity, posing research gaps to clini

57 Abuse-deterrent formulations of opioid analgesics (ADFs) were introduced to reduce opioi

58 The amount of opioid analgesic administered by the nurse correlated mo

59 Some antithrombotics, antibiotics, opioid analgesics, adrenergics, proton-pump inhibitors,

60 tructure-based allosteric drug design of non-opioid analgesic agents that are specific to disease con

61 R) is a promising therapeutic target for non-opioid analgesic agents to treat neuropathic pain(1,2).

62 Opioid analgesics altered dopamine negative responses to

63 to the suspension of therapy and a need for opioid analgesic and enteral/parenteral nutrition, with

64 nd drivers in 8.4% of person-crashes started opioid analgesics and 6.3% stopped opioid analgesics.

65 he mu opioid receptor, the primary target of opioid analgesics and abused drugs.

66 xone), the receipt of high-risk medications (opioid analgesics and benzodiazepines), and health care

67 l indicators of poor quality (prescribing of opioid analgesics and benzodiazepines).

68 A total of 452 691 261 prescriptions for opioid analgesics and buprenorphine for opioid use disor

69 PANTS: In this cross-sectional study, use of opioid analgesics and buprenorphine for opioid use disor

70 sectional study, existing patients receiving opioid analgesics and buprenorphine for opioid use disor

71 Prescriptions for opioid analgesics and buprenorphine for opioid use disor

72 upted medical care, impacting prescribing of opioid analgesics and buprenorphine for opioid use disor

73 reated due in part to reluctance about using opioid analgesics and fear that they will be abused.

74 data on misuse and diversion of prescription opioid analgesics and heroin.

75 classified as mild to moderate pain (for non-opioid analgesics) and strong to severe pain (for opioid

76 ain entails the use of nonopioid analgesics, opioid analgesics, and adjuvants singly or in combinatio

77 enzodiazepines, nonbenzodiazepine hypnotics, opioid analgesics, and other PDI medications in the 120

78 ems, sexual dysfunction, fatigue, receipt of opioid analgesics, and pain.

79 nal status, the need for corticosteroids and opioid analgesics, and survival time.

80 osteroids, immunostimulants (pegfilgrastim), opioids, analgesics, anxiolytics, antidepressants, antip

81 Opioid analgesics are commonly used in chronic pain mana

82 national expert groups have determined that opioid analgesics are essential for the relief of pain,

83 Opioid analgesics are frequently associated with gastroi

84 dal analgesic regimens continues to improve; opioid analgesics are increasingly taking on the role of

85 Opioid analgesics are powerful pain relievers; however,

86 Opioid analgesics are prescribed more frequently for pat

87 Opioid analgesics are the mainstay for POP management.

88 Opioid analgesics are the standard therapeutic agents fo

89 Opioid analgesics are traditionally the treatment for th

90 Although opioid analgesics are typically embraced as the mainstay

91 Opioid analgesics are used extensively in the management

92 Opioid analgesics are widely used as a treatment option

93 lead compound in the search for nonaddictive opioid analgesic as its signaling profile suggests that

94 clinical evidence still supports the use of opioid analgesics as the gold standard to treat cancer-r

95 nist-stimulated [(35)S]GTPgammaS binding and opioid analgesic assays; however, gene knockout of JNK 1

96 and 1483 children (2.3%) were exposed to an opioid analgesic at least once during gestation.

97 Prescription of opioid analgesics at discharge.

98 This article describes the major opioid analgesics available for the treatment of cancer-

99 Integrated Data Analysis System database on opioid analgesics between 2015 and 2019.

100 study investigated the acute effects of the opioid analgesic buprenorphine (Bup-SR-Lab) on diffuse n

101 Opioid analgesics cause severe side effects and accident

102 etermine contemporary trends and patterns of opioid analgesic consumption at the global, regional, an

103 Global opioid analgesic consumption increased from 2015 to 2019

104 In 2019, opioid analgesic consumption ranged from 0.01 MME per 10

105 Disparities in opioid analgesic consumption remained, indicating potent

106 Opioid analgesic consumption was measured in milligram m

107 The responses to the delta opioid analgesic [d-Pen(2),d-Pen(5)]enkephalin were unaf

108 response in HRPC patients with significant, opioid analgesic-dependent pain.

109 There is a wide range of opioid analgesics, differing in their chemical structure

110 ci previously shown to associate with higher opioid analgesic dose were associated with higher methad

111 Prescription of opioid analgesic drugs is a major contributing factor to

112 ntribute to the acute and chronic actions of opioid analgesic drugs.

113 ions are sorely needed to reduce reliance on opioid analgesic drugs.

114 pared between children of mothers exposed to opioid analgesics during pregnancy and children of mothe

115 Self-reported exposure to opioid analgesics during pregnancy, characterized in ter

116 sociated with an enhanced sensitivity to the opioid analgesic effect (IL-1beta, P = 0.0218; TNF-alpha

117 G9a inhibitors may be used to enhance the opioid analgesic effect in the treatment of chronic neur

118 role of G9a in diminished MOR expression and opioid analgesic effects in animal models of neuropathic

119 receptors (CBRs) have been implicated in the opioid analgesic effects.

120 gy to suppress neuroinflammation and enhance opioid analgesic efficacy.

121 mption and suggest new strategies to improve opioid analgesic efficacy.

122 ed hyperalgesia and tolerance and potentiate opioid analgesic efficacy.

123 lopment of therapies to maximize and sustain opioid analgesic efficacy.

124 ificant drug-drug interaction that modulates opioid analgesic efficacy.

125 The ultra-potent opioid analgesic, etorphine, elicits naloxone-reversible

126 higher risk of developing OUD and receiving opioid analgesics, even after accounting for comorbiditi

127 Opioid analgesics exert their therapeutic and adverse ef

128 asticity that are differentially affected by opioid analgesic exposure and are likely important media

129 t or refute the hypothesis that prescription opioid analgesic exposure in early pregnancy increases r

130 parenteral and transdermal delivery forms of opioid analgesics; external beam irradiation; and system

131 ies (K(a) ~ 100-200 M(-1)) for the synthetic opioid analgesic fentanyl.

132 ly has been aimed at the "Holy Grail" of the opioid analgesic field, namely the discovery of novel an

133 Opioid analgesic fills in the year before transplantatio

134 f bicyclic analogues of the bioisosteric non-opioid analgesics Flupirtine and Retigabine, previously

135 KPSC during the study period and ordered an opioid analgesic for eligible patients in 2018.

136 ventions to improve judicious prescribing of opioid analgesics for acute pain are needed owing to the

137 The prescribing of opioid analgesics for pain management-particularly for m

138 orting outcomes of RCT/s comparing 2 or more opioid analgesics for the management of chronic pain wer

139 low effectiveness of morphine and related mu opioid analgesics for the treatment of chronic inflammat

140 However, 59.6% disagreed with the use of opioid analgesics for treatment of those patients.

141 his large birth cohort, prenatal exposure to opioid analgesics had no substantial negative associatio

142 However, the misuse of opioid analgesics has contributed to the current opioid

143 Efforts to improve safety of u-opioid analgesics have focused on agonists that show sig

144 rs to be the highly connected specialty with opioid analgesic hydrocodone-acetaminophen to be the mos

145 t is involved in brain-to-blood transport of opioid analgesics (i.e., morphine).

146 uprenorphine (BSR) is used as a long-lasting opioid analgesic in common marmosets (Callithrix jacchus

147 which RGS proteins modulate the efficacy of opioid analgesics in a brain region- and agonist-selecti

148 -)-conolidine are potent and efficacious non-opioid analgesics in an in vivo model of tonic and persi

149 eir pharmacological profile against existing opioid analgesics in assays not confounded by limited si

150 ared the doses and duration of sedatives and opioid analgesics in patients receiving low vs. traditio

151 trolled trials of the efficacy and safety of opioid analgesics in people with cancer, approaches to o

152 However, consumption of opioid analgesics in the region is low and data suggest

153 imilar between children with any exposure to opioid analgesics in utero and children with only prepre

154 Strong opioid analgesics, including morphine, are the mainstays

155 ence from animal and human studies indicates opioid analgesics increase susceptibility to infections,

156 umber of drug abuse mentions per year due to opioid analgesics increased from 32,430 to 34,563 (6.6%)

157 Prescriptions for opioid analgesics increased substantially from 2002 thro

158 ical trial was designed to evaluate pain and opioid analgesic intake as surrogates for antitumor resp

159 Overall mean reductions in combined pain and opioid analgesic intake were greater for suramin plus HC

160 In addition to pain and opioid analgesic intake, prostate-specific antigen (PSA)

161 Novel, effective, non-opioid analgesic interventions are sorely needed to redu

162 Reducing EHR default dispense quantities for opioid analgesics is a feasible strategy that can be wid

163 Unintentional overdose involving opioid analgesics is a leading cause of injury-related d

164 nce and addiction disorders due to misuse of opioid analgesics is a major concern with pain therapeut

165 Abuse of prescription opioid analgesics is a serious threat to public health,

166 Thus, a strategy for improving the safety of opioid analgesics is needed.

167 While the therapeutic effect of opioids analgesics is mainly attributed to micro-opioid

168 Improgan, a non-opioid analgesic, is known to act in the rodent brain st

169 The choice of the opioid analgesic, its route of administration, dose, and

170 Opioid analgesics may be associated with increased risk

171 Paradoxically, repeated use of opioid analgesics may cause an exacerbated pain state kn

172 Such peripheral opioid analgesics may represent alternatives to presentl

173 The data suggest that spinal opioid analgesic mechanisms, acting alone or in synergy

174 46.8 [range, 0 to 110]; P<0.001), the use of opioid analgesics (median, 212 mg of morphine equivalent

175 almic medications (OR = 0.28, P < .001), non-opioid analgesic medications (OR = 0.21, P = .002), anti

176 und that cannabis use among adults receiving opioid analgesic medications was not associated with any

177 Worldwide, the use of prescription opioid analgesics more than doubled between 2001 and 201

178 iallodynic effects that last longer than the opioid analgesic morphine.

179 ents showed that acute administration of the opioid analgesic, morphine (5.6 mg/kg; IP), attenuated P

180 16.3%), neuroactive agents (n = 14; 16.3%), opioid/analgesics (n = 13; 15.1%), and cardiovascular ag

181 ic efficacy of two other predominantly kappa-opioid analgesics, nalbuphine and butorphanol; was compa

182 lly related alkaloids have been described as opioid analgesics, no therapeutically relevant propertie

183 ntation of these patients and the effects of opioid analgesics on mu-opioid receptors.

184 Opioid analgesics, once considered the standard approach

185 tive worsening, nor did individuals who used opioid analgesics or other pain-modulating drugs such as

186 2.0; 95% CI, 1.2 to 3.2), and treatment with opioid analgesics (OR, 1.6; 95% CI, 1.0 to 2.5).

187 CLINICAL QUESTION Do the benefits of opioid analgesics outweigh the risks in patients with pe

188 annabis laws experienced slower increases in opioid analgesic overdose mortality.

189 A single in vivo exposure to the opioid analgesic oxycodone disrupted mu OP-LTD and endoc

190 roducts and formulations of six prescription opioid analgesics: oxycodone, hydrocodone, hydromorphone

191 , including psychoactive substances, such as opioid analgesics, phenethylamines, and cathinone deriva

192 Prescription opioid analgesics play an important role in the treatmen

193 nted association between prenatal prescribed opioid analgesic (POA) exposure and neurodevelopmental d

194 Published research on prescribed opioid analgesic (POA) use during pregnancy and birth ou

195 eal potential novel strategies for improving opioid analgesic potency and safety.

196 Adherence rates for opioid analgesics prescribed on an around-the-clock (ATC

197 The primary outcome was the quantity of opioid analgesics prescribed with the new default prescr

198 mbers aged 18 years or older who received an opioid analgesic prescription during the study period.

199 Overall, 21 331 patients received a new opioid analgesic prescription from 490 prescribers.

200 se after implementation of a law restricting opioid analgesic prescriptions in Florida.

201 default dispense quantity of 10 tablets for opioid analgesic prescriptions led to a modest reduction

202 A default dispense quantity for new opioid analgesic prescriptions of 10 tablets (interventi

203 Overall adherence rates for ATC opioid analgesics ranged from 84.5% to 90.8% and, for PR

204 Opioid analgesics remain the choice for the treatment of

205 Opioid analgesics remain the gold standard for intractab

206 The pursuit of non-addictive opioid analgesics remains unattained due to the unresolv

207 underlying different side effect profiles in opioid analgesics remains unknown.

208 Secondary outcomes were opioid analgesic reorders and health service use within

209 Overall opioid analgesic sales in the 66 countries or regions in

210 Opioid analgesics such as morphine act through mu-opioid

211 in-coupled receptor (GPCR), is the target of opioid analgesics such as morphine and fentanyl.

212 t evidence suggests that chronic exposure to opioid analgesics such as morphine disrupts the intestin

213 -2 positively modulates the actions of other opioid analgesics, such as fentanyl and methadone.

214 IGNIFICANCE STATEMENT Commonly used clinical opioid analgesics, such as fentanyl and morphine, can pr

215 eltaR antinociception.SIGNIFICANCE STATEMENT Opioid analgesics, such as morphine, which target the mu

216 r the discovery and development of novel non-opioid analgesics, such as subtype-selective sodium chan

217 asurements, demonstrated that it was a safer opioid analgesic than morphine in pain control.

218 ain higher and be more willing to administer opioid analgesics than were physicians.

219 Morphine is a unique opioid analgesic that activates the mu-opioid receptor (

220 he mechanisms involved in adverse effects of opioid analgesics that could assist in the development o

221 he mechanisms involved in adverse effects of opioid analgesics that could assist in the development o

222 The design of opioid analgesics that demonstrate selectivity for indiv

223 The design of opioid analgesics that demonstrate selectivity for indiv

224 Hospital-initiated opioid analgesics that extend beyond discharge can lead

225 aches epidemic levels, the identification of opioid analgesics that lack abuse potential may provide

226 The generation of potent opioid analgesics that lack the side effects of traditio

227 esirable for the development of long-lasting opioid analgesics that remain sensitive to antagonist re

228 reased abuse potential compared with current opioid analgesics that target the mu opioid receptor.

229 ts the randomization criteria (i.e. need for opioid analgesics) the patient will be randomized to eit

230 often successfully treated with prescription opioid analgesics, they are also at high risk for opioid

231 isease (SCD), for which patients may require opioid analgesics throughout life.

232 r that was recently approved by FDA as a non-opioid analgesic to treat moderate to severe acute pain.

233 le to develop a truly effective and safe non-opioid analgesic to treat POP and other forms of pain.

234 somewhere between the two extremes in using opioid analgesics to cope with their psychological or sp

235 imal therapeutic profile, the search for non-opioid analgesics to replace these well-established ther

236 ntensity and were more willing to administer opioid analgesics to them than to their demographic coun

237 o its chronicity and the limited efficacy of opioid analgesics to treat neuropathic pain.

238 Given the reduced efficacy of opioid analgesics to treat neuropathic, compared with in

239 ing could reduce the need for large doses of opioid analgesics to treat pain by producing an opioid-s

240 The trend of increasing medical use of opioid analgesics to treat pain does not appear to contr

241 pioid receptor (MOR), the primary target for opioid analgesics, to define a signaling pathway that dy

242 d central pathway subserving the associative opioid analgesic tolerance (AOAT) remains unclear.

243 lead to further evaluate the role of P-gp in opioid analgesic tolerance development.

244 Opioid analgesic tolerance, a root cause of opioid overd

245 across different brain regions distinct for opioid analgesic tolerance.

246 (P = .01) was observed between reductions in opioid analgesic use and pain scores only for those pati

247 tile range, 4 to 34), and 38% of the men had opioid analgesic use at baseline.

248 perative ileus (POI) is often exacerbated by opioid analgesic use during and following surgery, since

249 fect (NTD) risk associated with prescription opioid analgesic use during early pregnancy.

250 so in secondary analyses, mean cumulative IV opioid analgesic use was reduced by 83% with GMI-1070 vs

251 status, disease site, lactate dehydrogenase, opioid analgesic use, albumin, hemoglobin, prostate-spec

252 Opioid analgesic use, average mouth and throat soreness

253 for depression, cognitive dysfunction, pain, opioid analgesics use, and sleep disorders (p-interactio

254 nonpharmacological interventions to decrease opioid analgesics use, as they have significant adverse

255 s in the diversion and abuse of prescription opioid analgesics using data through 2013.

256 years; 1 121 004 women [58.9%]) in which an opioid analgesic was prescribed.

257 he mean per capita weighted total DDD of non-opioid analgesics was 0.029 DDD/day/person, and that of

258 The need for corticosteroids and opioid analgesics was significantly reduced in the surgi

259 ates, both short-term and longer-term use of opioid analgesics were associated with hip fracture even

260 vious study of rheumatology clinic patients, opioid analgesics were found to be highly effective, pro

261 lion total morphine milligram equivalents of opioid analgesics were prescribed weekly vs 1843 million

262 Opioid analgesics were taken by 275 decedents (93.2%), o

263 lasses (anticoagulants, diabetes agents, and opioid analgesics) were implicated in an estimated 59.9%

264 -clinical profile of a highly effective, non-opioid analgesic when administered into the rodent CNS.

265 n the chemical synthesis of desmethylprodine opioid analgesic, which induces Parkinson disease.

266 ve pain management due to adverse effects of opioid analgesics, which can impede recovery; a problem

267 Despite the skilled use of opioid analgesics, which is crucial to the relief of can

268 Thus, [Dmt(1)]DALDA is a highly selective mu-opioid analgesic with significant pharmacological differ

269 These results show that dipyrone, a non-opioid analgesic with widespread use in Europe and Latin

270 peutic targets, as illustrated by our unique opioid analgesics with a vastly improved pharmacological

271 ection among patients initiating long-acting opioid analgesics with and without previously reported i

272 Opioid analgesics with both micro and delta opioid recep

273 a promising strategy for the development of opioid analgesics with fewer side effects.

274 eld, namely the discovery of novel and safer opioid analgesics with improved opioid-related adverse e

275 gstanding interest in the development of new opioid analgesics with improved therapeutic profiles.

276 The development of opioid analgesics with reduced adverse effects is an unm

277 t/DOR antagonist ligands may emerge as novel opioid analgesics with reduced side effects.

278 ents a promising lead for the development of opioid analgesics with reduced side effects.

279 thus a promising lead for the development of opioid analgesics with reduced tolerance.

280 ligand discovery community to produce novel opioid analgesics with superior opioid-related adverse-e

281 opioid ligand strategy for the discovery of opioid analgesics with superior preclinical therapeutic

282 we observed increased intrinsic efficacy of opioid analgesics with two antinociceptive tests: hot wa

283 no previous research has substantiated safe opioid analgesics without abuse liability in primates.

284 , opening avenues for the development of non-opioid analgesics without affecting CBT.